explore -WSS

explore

author：knowledge 2025-10-01 15:29:32 - browse：57

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Senate panel to vote on hospitals, PBMs, prisoner care

leisure time

WSS

FDA's Woodcock to retire early next year

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Diversifying clinical trials isn't enough to close racial gaps: study

Hospitals look to new technology to keep health care workers safe

First Opinion Podcast: How to protect health care in times of war

hotspot

explore

entertainment

Walensky prepares to leave CDC — and Congress — behind

Does good food count as health care? Study aims to find out

Supreme Court strikes down use of affirmative action

WHO may add ‘noma' to its list of neglected tropical diseases

BioMarin wins approval for gene therapy to treat hemophilia A

In key trial, Verve's treatment lowers cholesterol levels in patients

Medicare details structure of new drug price negotiation program

Does good food count as health care? Study aims to find out

How one medical school became remarkably diverse

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

focus

Physician subsidies by hospitals soar in wake of No Surprises Act

Surge of respiratory disease in China has likely explanation

FDA has safety concerns on CRISPR

Astellas still sees hope in its gene therapy after four deaths

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Does good food count as health care? Study aims to find out

focus

leisure time

leisure time

focus